Putin almost looks like he's had a stroke. Or he has been diagnosed with cancer. He has a weird fatalistic look. Probably time the Generals think about taking him out.
That's a good insight. And not questioning it, but I wonder how that applies to the other 500 categories they have. I mean apparel is just a tiny part of ebay. But still, thumbs up on the Peter Lynch type write-up. ----The Butterfly reported tonight. I haven't looked yet. ----SAIL. I saw that earlier today when I was looking at who was reporting. I thought it rang a bell. Sounds familiar. I probably lost money on it. I'm in Stoney! Can we bring Nassatasia in too? She wants out of that part of the world anyway.
If you recall I remained mum on Uber until $33 at which point it got the blessing. Another 10% winner for The Savant. Josh B has always been a big fan of LYV fwiw. And speaking of, someone called in to Cramer tonight right after he did his opening bit. The one call he always takes at the beginning of the show. Know what they asked about? And I swear it was a granny by her voice lol... Restoration Hardware. Ol' Jim couldn't say enough good things. RH>>>>> $401
My lord what a hangover. What happened last night I'm going through my emails and I was a crazy man. These poor Seet Geek people. Email header-- YOU OWE ME! $$$$$. I'll spare you all the details and cut to the chase -- I have the tickets on my wife's phone in my ticketmaster app even though I didn't buy them through ticketmaster. The large box which contains a pair of very high women's boots I still have-- Mrs Stoney didn't deserve them last night.... Aqua Metals produces first lithium from spent batteries 08:03 AQMS-! Up 16% yesterday.> ACV Auctions initiated with a Buy at Needham, added to Conviction List 07:20 ACVA, Ok this is a stock I am interested in. I have covered it twice before. There are a bunch of car auction stocks but this one stands out. Just recently over the past month I came very close to buying. AbbVie price target raised to $170 from $155 at Citi 07:19 ABBV Citi analyst Andrew Baum… !!! Ok this helps,..... $150 looks tough to get through.... Dave & Buster's added to Analyst Current Favorites list at Raymond James 07:43 PLAY Raymond James analyst Brian Vaccaro reiterated a Strong Buy rating on Dave & Buster's and added the stock to the Analyst Current Favorites List ahead of the company's Q4 report expected in late March. The omicron recovery trade has gained traction in recent weeks, and Vaccaro sees room for additional gains ahead, the analyst tells investors in a research note. Shift4 Payments announces two acquisitions to expand international payments 07:37 FOUR Shift4 American Lithium appoints DRA Global as project lead to finalize TLC PEA 07:28 LIACF Bentley Systems sees FY22 revenue $$1.11B -$1.14B, consensus $1.09B 07:27 BSY Sees total revenues in the range of $1.11B to $1.14B, representing growth of 15.0% to 18.1%. Sees FY22 adjusted EBITDA in the range of $370M to $380M, representing growth of 13.9% to 16.9%, and Adjusted EBITDA margin of approximately 33%. Bently is a Van stock from The Phantasma thread, I always liked these guys once I started looking into them... lots of hidden angles. Bit of Leidos Bit of PLTR... Bit of software..... SailPoint price target raised to $57 from $50 at Canaccord 07:24 SAIL Canaccord analyst .… Just kind of annoying to be right all along but have the stock sell off the way it did prior... I was forced out on the way down, now of course back past my buy point.... View Inc. announces Smart Windows installed in Lake Nona Wave Hotel 07:22 VIEW Shift4 Payments sees FY22 revenue $1.9B-$2B, consensus $1.94B 07:21 FOUR Sees FY22 end-to-end payment volume $68B-$70B. Sees FY22 adjusted EBITDA $240M-$250M. NextCure initiated with Buy, $16 price target at Ladenburg 06:50 NXTC Ladenburg Thalmann analyst Aydin Huseynov initiated coverage of NextCure with a Buy rating and $16 price target. The analyst views NextCure as a "cutting-edge innovative biotech company that is trading below cash on the balance sheet which is likely due to low expectations of investors regarding its lead candidates." Huseynov's investment thesis is around the company's lead candidate NC318 and its clinical efficacy in the non-small cell lung cancer indication, saying prior studies showed "convincing clinical activity." Molson Coors' Coors Light eliminates 6-pack plastic rings globally 06:22 TAP Snap initiated with a Buy at Benchmark 06:17 SNAP ACV Auctions to hold a virtual analyst day 04:55 ACVA Virtual Analyst Day to be held on March 1 at 1 pm. Ok we had good earnings just recently. We have that upgrade today and we have a analyst day at 1 pm.... Lets consider the move of buying into weakness early today & then hope they hit the ball out of the park at their virtual analyst day... ~si
It's funny I have has a history with tinted glass.. Research Frontiers in the old days here at ET and now I love this little VIEW.